Skip to main content

Advertisement

SpringerLink
Log in

Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Makita S, Tobinai K (2017) Clinical features and current optimal management of natural killer/T-cell lymphoma. Hematol Oncol Clin North Am 31:239–253

    Article  PubMed  Google Scholar 

  2. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K (2009) Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594–5600

    Article  PubMed  CAS  Google Scholar 

  3. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410–4416

    Article  PubMed  CAS  Google Scholar 

  4. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351–2356

    Article  PubMed  CAS  Google Scholar 

  5. Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K (2005) Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 130:860–868

    Article  PubMed  CAS  Google Scholar 

  6. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST, Asian Oncology Summit (2009) Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1093–1101

    Article  PubMed  Google Scholar 

  7. Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, Yoon DH, Tang T, Cho J, Park S, Ko YH, Kim SJ, Suh C, Lin T, Kim WS (2017) Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol 28:2199–2205

    Article  PubMed  CAS  Google Scholar 

  8. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS (2009) Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 27:6027–6032

    Article  PubMed  CAS  Google Scholar 

  9. Michot JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V (2015) Concurrent etoposide, steroid, high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. Eur J Cancer 51:2386–2395

    Article  PubMed  CAS  Google Scholar 

  10. Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, Kojima H, Sobue R, Matsui T, Ino T (1994) Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki 35:635–641

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Junko Watanabe, Shinichi Makita, Yuta Ito, Shunsuke Hatta, Tomotaka Suzuki, Sayako Yuda, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama & Koji Izutsu

  2. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Tomotaka Suzuki & Sung-Won Kim

  3. Department of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Sayako Yuda & Akiko Miyagi Maeshima

Authors
  1. Junko Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinichi Makita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuta Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shunsuke Hatta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomotaka Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sayako Yuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akiko Miyagi Maeshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Suguru Fukuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wataru Munakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tatsuya Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dai Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sung-Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Koji Izutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinichi Makita.

Ethics declarations

Conflict of Interest

JW, SM, YI, SH, ToS, SY, AMM, SF, WM, TaS, and SWK declare no conflicts of interests. DM has received personal fees from Takeda, Janssen, Eisai, Biomedis International, Celgene, Sanofi, Kyowa Hakko Kirin, Fujifilm, Mochida, Ono, Mundipharma, and Chugai; and research finding from GlaxoSmithKline, SERVIER, Abbvie, MSD, Kyowa Hakko Kirin, Ono, and Chugai, outside the submitted work. KI has received personal fees from Kyowa Hakko Kirin, Bristol-Myers, and Shionogi, outside the submitted work.

Research involving humans or animals

Not applicable

Informed consent

Written informed consent was obtained from the patient.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Watanabe, J., Makita, S., Ito, Y. et al. Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase. Ann Hematol 97, 1739–1740 (2018). https://doi.org/10.1007/s00277-018-3335-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3335-4

Search

Navigation